Albemarle said net sales for Q3 2025 were $1,307.8 million, down 3.5% from $1,354.7 million in the prior-year quarter, and net loss attributable to Albemarle was $(160.7) million.

1. 01

   Albemarle said net sales for Q3 2025 were $1,307.8 million, down 3.5% from $1,354.7 million in the prior-year quarter, and net loss attributable to Albemarle was $(160.7) million.

2. 02

   The company said it recognized a non-cash goodwill impairment charge of $181.1 million ($175.7 million after tax, or $1.49 per share) related to the Ketjen Refining Solutions reporting unit in Q3 2025.

3. 03

   Albemarle said cash from operations for Q3 was $356 million, up 57%, and reduced its full-year 2025 capital expenditures outlook to approximately $600 million while expecting full-year free cash flow of $300 to $400 million.

4. 04

   The company announced on October 27 agreements to sell stakes in Ketjen and the Eurecat joint venture for combined pre-tax proceeds of approximately $660 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.